

Kymera Therapeutics, Inc. (KYMR)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001815442

Kymera Therapeutics, Inc.
KYMR; healthcare

Grade

C

A B C D E

middle fifth of 371 graded peers
percentile 47.8; sampling error 2.5 points; lower is stronger

Rank

178 of 371

Profitability

D

+ + + + | ————

percentile 77.4

Solvency

A

| ———+ + + + ———+

percentile 12.0

Growth and financing

C

————| ———+ + + ———

percentile 52.0

Reliability

0.91 AUC

filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025

Peer failure rate

1.01% a year

Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

\$591M to \$2.67B assets

total assets \$1.7B

Standard universe

inside

revenue above \$1M and assets above \$10M

Warnings

dilution

not computable: distress, fortress balance sheet

Inputs computable

7 of 14

Graded from

filings received through Feb 26, 2026

225 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026

Last close

\$109.34

2026-10-08; market equity \$9.1B

Price used in grade

None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: C/D from Mar 21, 2025, C from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients' lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to

discover and develop a new generation of medicines in a disease-agnostic manner.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 77.4						
Gross profitability		0.0%	32.2%	95.8	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(5.8%)	(6.6%)	58.9	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 2
Solvency, sleeve percentile 12.0						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		9.79	(0.31)	9.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		10.47x	2.96x	15.0	839	2025-12-31
Growth and financing, sleeve percentile 52.0						
Revenue growth, three-year compound		(5.7%)	10.0%	80.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		42.4%	2.1%	9.8	704	2025-12-31
Net share issuance, one year		25.7%	2.5%	65.4	634	2026-02-20


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 25.7%

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
173	Enovis Corp. (ENOV)	46.5	C	
174	Align Technology Inc. (ALGN)	46.8	C	
175	ClearPoint Neuro, Inc. (CLPT)	47.0	C	
176	Anika Therapeutics, Inc. (ANIK)	47.3	C	fortress
				balance sheet
177	Davita Inc. (DVA)	47.6	C	
178	Kymera Therapeutics, Inc. (KYMR) <	47.8	C	dilution
179	Scynexis Inc. (SCYX)	48.1	C	fortress
				balance sheet
180	Amneal Pharmaceuticals, Inc. (AMRX)	48.4	C	
181	Macrogenics Inc. (MGNX)	48.6	C	
182	Savara Inc. (SVRA)	48.9	C	short runway,
				fortress
				balance sheet
183	Biodesix Inc. (BDSX)	49.2	C	dilution

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	109.9%	8.0%	90
Distance from 52-week high	(14.1%)	(31.4%)	75
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(2.6%)	(1.0%)	47
Book value to price	0.17	0.28	36
Sales to price	0.00	0.31	4
Composite equity issuance, five years	61.8%	20.3%	69
Relative strength against the sector, log excess return	0.53	(0.14)	90

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$124.5M
Operating cash flow, four quarters	-\$236.8M

Months of runway	6.3
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$71.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$39.2M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
2	cost of revenue	us-gaap:CostOfRevenue	\$39.2M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
3	assets	us-gaap:Assets	\$1.7B	2025-12-31	2026-02-26	10-K	0001193125-26-073395
4	net income	us-gaap:NetIncomeLoss	-\$311.4M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$232.9M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
6	assets	us-gaap:Assets	\$978.0M	2024-12-31	2026-02-26	10-K	0001193125-26-073395
7	current assets	us-gaap:AssetsCurrent	\$871.2M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
8	current liabilities	us-gaap:LiabilitiesCurrent	\$83.2M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.1B	2025-12-31	2026-02-26	10-K	0001193125-26-073395
10	operating income	us-gaap:OperatingIncomeLoss	-\$349.4M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
11	book equity	us-gaap:StockholdersEquity	\$1.6B	2025-12-31	2026-02-26	10-K	0001193125-26-073395
12	liabilities	us-gaap:Liabilities	\$163.1M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$47.1M	2024-12-31	2026-02-26	10-K	0001193125-26-073395
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$78.6M	2023-12-31	2026-02-26	10-K	0001193125-26-073395
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$46.8M	2022-12-31	2025-02-27	10-K	0000950170-25-028355
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.4M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$194.5M	2024-12-31	2026-02-26	10-K	0001193125-26-073395
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12.8M	2024-12-31	2026-02-26	10-K	0001193125-26-073395
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$102.8M	2023-12-31	2026-02-26	10-K	0001193125-26-073395
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$34.5M	2023-12-31	2026-02-26	10-K	0001193125-26-073395
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$153.1M	2022-12-31	2025-02-27	10-K	0000950170-25-028355
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.8M	2022-12-31	2025-02-27	10-K	0000950170-25-028355
23	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$8.3M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$311.4M	2025-12-31	2026-02-26	10-K	0001193125-26-073395
25	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-02-26	10-K	0001193125-26-073395
26	current assets	us-gaap:AssetsCurrent	\$510.3M	2024-12-31	2026-02-26	10-K	0001193125-26-073395
27	current liabilities	us-gaap:LiabilitiesCurrent	\$67.8M	2024-12-31	2026-02-26	10-K	0001193125-26-073395
28	assets	us-gaap:Assets	\$575.8M	2023-12-31	2025-02-27	10-K	0000950170-25-028355
29	assets	us-gaap:Assets	\$603.1M	2022-12-31	2024-02-22	10-K	0000950170-24-018414
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	81,642,394	2026-02-20	2026-02-26	10-K	0001193125-26-073395
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	64,944,136	2025-02-21	2025-02-27	10-K	0000950170-25-028355